Rather, it is plausible, given that BAP1 wild-type tumors appear to be more sensitive to combined HDAC and PD-1 inhibition in this trial, that the immune modulatory functions of HDAC inhibitors rather than their direct tumor cell-killing effect may be dominant. This evidence concerns the gene HDAC9 and neoplasm.